drugset
drugset / Trial / NCT06951997

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

NCT06951997 ↗

Phase 2 Recruiting 33 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.

Timeline

Start
2025-03-07
Primary completion
2027-05-15
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Nab-paclitaxel Small molecule 125 mg/m2 —
Subject QL1706 Monoclonal antibody 5 mg/kg —
Subject Tucidinostat Small molecule 20 mg —

Indications

pancreatic ductal adenocarcinoma